IDH1 and central nervous system cancer: Each gene or pathway was tested as a survival and tumor grade biomarker in the gliomas and in their diagnostic subgroups (IDH mutant or wild type, IDH mutant with 1p/19q co-deletion, MGMT promoter methylated or unmethylated), and also in the three specific GBM molecular subtypes (proneural, mesenchymal, classical).